04/25/2024
Policy Forum
Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
Image credit: Mikhail Nilov, Pexels
Connect with Us